Le Lézard
Classified in: Health
Subject: ATY

ALEXION INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alexion Pharmaceuticals, Inc. - (ALXN)

NEW ORLEANS, Oct. 6, 2017 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN).

Kahn Swick & Foti, LLC ("KSF") - - not all law firms are created equal.  Visit www.ksfcounsel.com to learn more about KSF. (PRNewsfoto/Kahn Swick & Foti, LLC)

Since late 2016, the Company has been the subject of investigations by numerous legal and regulatory authorities and significant litigation relating to its use of a myriad of unethical and possibly illegal sales and promotion campaigns by its salespeople in connection with its flagship drug, Soliris.

The actions of the Company, as directed by its executives, have exposed it to significant financial losses, an exodus of high-level executives, investigations by the U.S. Securities and Exchange Commission, the U.S. Department of Justice, the U.S. Attorney's Office for the District of Massachusetts, the U.S. Department of Health and Human Services and Brazilian law enforcement officials.  Further, the Company has been sued in an ongoing securities class action lawsuit for failing to disclose material information and has also received a formal demand for inspection of its books and records made by a shareholder.  Recently, a shareholder derivative lawsuit was filed against the Company's current and former executives. 

KSF's investigation is focusing on whether Alexion's officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Alexion shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com).

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.


Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
206 Covington St.
Madisonville, LA 70447


SOURCE Kahn Swick & Foti, LLC

These press releases may also interest you

at 00:19
Erie Meat Products Ltd. is recalling Butcher's Selection brand Stampede Chicken Burgers from the marketplace because they may contain egg which is not declared on the label. People with an allergy to egg should not consume the recalled product...

16 mar 2018
Constellation Healthcare Technologies, Inc. ("Constellation" or "the Company"), a healthcare services organization providing outsourced revenue cycle management, practice management, and group purchasing services to U.S. physicians, along with...

16 mar 2018
The Spice Tailor (Canada) Limited is recalling The Spice Tailor brand Fiery Goan Curry from the marketplace because it contains mustard which is not declared on the label. People with an allergy to mustard should not consume the recalled product...

16 mar 2018
The "Cleanroom Technology Market by Type (Consumables, Equipment), by Construction, by End User, by Geography - Global Market Size, Share, Development, Growth and Demand Forecast, 2013-2023" report has been added to ResearchAndMarkets.com's offering....

16 mar 2018
"The CAP applauds the Centers for Medicare & Medicaid Services (CMS) for revising its final national coverage determination (NCD) policy for next-generation sequencing (NGS) to address some of the concerns raised by the CAP and other stakeholders....

16 mar 2018
The "Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018" report has been added to ResearchAndMarkets.com's offering. The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2012 to 2018...

News published on 6 october 2017 at 22:50 and distributed by: